A I Burnasyan Federal Medical Biophysical Center Clinical Bulletin最新文献

Occupational Pathology Service of FMBA of Russia 俄罗斯工商管理硕士职业病理学服务处

A I Burnasyan Federal Medical Biophysical Center Clinical Bulletin Pub Date : 2023-10-01 DOI: 10.33266/2782-6430-2023-3-5-13

A.Y. Bushmanov, A.S. Kretov, I.V. Vlasovа, A.A. Lomteva, A.A. Vyunova, E.E. Adeninskaya, N.I. Simonova, L.V. Sokolovskaya

{"title":"Occupational Pathology Service of FMBA of Russia","authors":"A.Y. Bushmanov, A.S. Kretov, I.V. Vlasovа, A.A. Lomteva, A.A. Vyunova, E.E. Adeninskaya, N.I. Simonova, L.V. Sokolovskaya","doi":"10.33266/2782-6430-2023-3-5-13","DOIUrl":"https://doi.org/10.33266/2782-6430-2023-3-5-13","url":null,"abstract":"All the centers of occupational pathology of the FMBA of Russia have been established on the basis of multidisciplinary specialized healthcare institutions. The chief freelance professional pathologist annually collects reports on the results of the centers of occupational pathology. According to the data of the Centers of Occupational Pathology of the FMBA of Russia, the profile of the causes of medical contraindications has its own characteristics. The most common causes of medical contraindications include: diseases of the circulatory system, diseases of the eye and its appendage, neoplasms, diseases of the ear and mastoid process, diseases of the blood, hematopoietic organs and individual disorders involving the immune mechanism, which necessitates the implementation of preventive programs in the indicated directions. The main classes of chronic somatic diseases first identified during medical examinations include: diseases of the digestive system, diseases of the endocrine system, eating disorders and metabolic disorders, diseases of the eye and its accessory apparatus, diseases of the circulatory system. In 2022, 8725 examinations of aptitude and connection of the disease with the profession were conducted in the Centers of Occupational Pathology within the established scope of the state task, 514 of them examinations of aptitude for complex cases, 908 examinations of the connection of the disease with the profession.","PeriodicalId":472385,"journal":{"name":"A I Burnasyan Federal Medical Biophysical Center Clinical Bulletin","volume":"42 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135661815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Burden of Orthostatic Hypotension in the Elderly 老年人直立性低血压的负担

A I Burnasyan Federal Medical Biophysical Center Clinical Bulletin Pub Date : 2023-10-01 DOI: 10.33266/2782-6430-2023-3-18-20

A.T. Betuganova, Z.A. Barkhanoeva, T.A. Martynova

引用次数: 0

Aspects of the Use of Antithrombotic Therapy in Vascular Neurology 抗血栓治疗在血管神经学中的应用

A I Burnasyan Federal Medical Biophysical Center Clinical Bulletin Pub Date : 2023-10-01 DOI: 10.33266/2782-6430-2023-3-21-26

O.V. Karpova, E.V. Bril’

引用次数: 0

Merkel Cell Carcinoma: Current Trends in Medical Practice 默克尔细胞癌:医疗实践的当前趋势

A I Burnasyan Federal Medical Biophysical Center Clinical Bulletin Pub Date : 2023-10-01 DOI: 10.33266/2782-6430-2023-3-30-34

D.A. Andreev, A. A. Zavyalov

{"title":"Merkel Cell Carcinoma: Current Trends in Medical Practice","authors":"D.A. Andreev, A. A. Zavyalov","doi":"10.33266/2782-6430-2023-3-30-34","DOIUrl":"https://doi.org/10.33266/2782-6430-2023-3-30-34","url":null,"abstract":"Merkel cell carcinoma (CM) is a rare but very dangerous (rapidly progressive) malignancy. The need for early detection of CM determines the importance and relevance of informing dermatologists, cosmetologists, doctors of other specialties about the current aspects of the diagnosis and treatment of this disease, despite its relatively rare occurrence. The review highlights modern approaches to the diagnosis and treatment of CM. Early treatment of CM is vital because the disease progresses extremely rapidly with the formation of distant metastases. For the treatment of CM at localized stages, positive results in terms of prognosis in patients are brought by the use of the standard of combined treatment: surgery with adjuvant radiation therapy. A good alternative is also to use of RT only. Effective therapy for late variants of CM includes the appointment of immune response checkpoint inhibitors. Immunotherapy provides a sustained response in a significant proportion of patients with metastatic or recurrent disease. However, in the population of elderly and debilitated patients, the use of immunotherapy is limited due to the development of adverse events. The tasks of determining the optimal therapy regimens with the best efficacy and drug safety profiles have been included in the programs for further clinical research and development.","PeriodicalId":472385,"journal":{"name":"A I Burnasyan Federal Medical Biophysical Center Clinical Bulletin","volume":"38 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135663092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bronchial Fistula is a Formidable and Insidious Complication in Oncological Practice 支气管瘘是肿瘤临床中一种令人生畏的潜在并发症

A I Burnasyan Federal Medical Biophysical Center Clinical Bulletin Pub Date : 2023-10-01 DOI: 10.33266/2782-6430-2023-3-41-46

G.A. Baksiyan, A.A. Zavialov

{"title":"Bronchial Fistula is a Formidable and Insidious Complication in Oncological Practice","authors":"G.A. Baksiyan, A.A. Zavialov","doi":"10.33266/2782-6430-2023-3-41-46","DOIUrl":"https://doi.org/10.33266/2782-6430-2023-3-41-46","url":null,"abstract":"Bronchopleural fistula is one of the most dangerous complications in thoracic surgery and can occur both in the early postoperative period (especially in the first 7-10 days after surgical treatment) and many years after surgery. In most cases, the appearance of a bronchial fistula is associated with the progression of the oncological process, post-radiation changes in the bronchus stump, and also with a persistent pulmonary infection. The incidence of bronchus suture failure after pneumonectomy for non-small cell lung cancer is 1.5-12.5%, after lobectomy – 1-4%. Among the predictors of the development of this complication, there are: male sex, age over 65 years, patients with severe (ASA 3 or higher) and numerous concomitant diseases, right-sided and extended operations, combined antitumor treatment. A special role in the prevention of the development of bronchopleural fistula is given to surgical techniques for covering the bronchus stump with various tissues, mainly the pleura or muscles. The treatment of bronchial fistula involves the relief of the general inflammatory reaction, the sanitation of the residual pleural cavity and the direct closure of the defect, using various options for broncho- and thoracoplasty.","PeriodicalId":472385,"journal":{"name":"A I Burnasyan Federal Medical Biophysical Center Clinical Bulletin","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135663189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

COVID19 Coronavirus Infection in Patients with Acute Myeloid Leukemia: Literature Review and Own Experience 急性髓系白血病患者感染covid - 19冠状病毒:文献综述及自身体会

A I Burnasyan Federal Medical Biophysical Center Clinical Bulletin Pub Date : 2023-10-01 DOI: 10.33266/2782-6430-2023-3-47-54

D.E. Gagloeva, E.N. Misyurina, E.I. Zhelnova, T.N. Tolstyh, E.R. Rogacheva, T.A. Astrelina

{"title":"COVID19 Coronavirus Infection in Patients with Acute Myeloid Leukemia: Literature Review and Own Experience","authors":"D.E. Gagloeva, E.N. Misyurina, E.I. Zhelnova, T.N. Tolstyh, E.R. Rogacheva, T.A. Astrelina","doi":"10.33266/2782-6430-2023-3-47-54","DOIUrl":"https://doi.org/10.33266/2782-6430-2023-3-47-54","url":null,"abstract":"The presented literature review presents studies, including our own, on the peculiarities of the course of coronavirus infection in patients with hematological malignancies, in particular in patients with acute myeloid leukemia (AML). A modern classification of AML is presented. It has been shown that in patients with AML, the addition of coronavirus infection SARS-CoV-2 COVID-19 significantly worsens the prognosis of the patient’s life, which makes significant changes in overall survival and mortality. Factors worsening the prognosis of life in patients with AML are advanced age, comorbidities, AML out of remission, the critical course of SARS-CoV-2 COVID19, interruption of treatment without subsequent resumption. In patients with AML and SARS-CoV-2 COVID19, the most optimal treatment tactic is temporary discontinuation of the course of chemotherapy followed by resumption after the regression of the viral infection (both at the onset of the disease and when chemotherapy is already underway). If it is not possible to postpone the course of chemotherapy, treatment can and should be carried out with the provision of adequate accompanying therapy simultaneously with ethological and pathogenetic therapy for SARS-CoV-2 COVID19. Even in the presence of hematological contraindications in patients with AML, SARS-CoV-2 COVID19 treatment should be carried out in full according to clinical guidelines for the treatment of SARS-CoV-2 COVID19.","PeriodicalId":472385,"journal":{"name":"A I Burnasyan Federal Medical Biophysical Center Clinical Bulletin","volume":"70 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135663184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Results of the ESMO Congress: Immunotherapy for NSCLC ESMO大会结果:非小细胞肺癌的免疫治疗

A I Burnasyan Federal Medical Biophysical Center Clinical Bulletin Pub Date : 2023-10-01 DOI: 10.33266/2782-6430-2023-3-55-60

D.A. Andreev, A. A. Zavyalov, S.E. Varlamova

引用次数: 0

Features of Elderly Patients: How to Take Them into Account When Prescribing Anticoagulant Therapy?! 老年患者的特点:如何在处方抗凝治疗时考虑这些特点?

A I Burnasyan Federal Medical Biophysical Center Clinical Bulletin Pub Date : 2023-10-01 DOI: 10.33266/2782-6430-2023-3-35-40

A.A. Zavialov, I.V. Gribkova

{"title":"Features of Elderly Patients: How to Take Them into Account When Prescribing Anticoagulant Therapy?!","authors":"A.A. Zavialov, I.V. Gribkova","doi":"10.33266/2782-6430-2023-3-35-40","DOIUrl":"https://doi.org/10.33266/2782-6430-2023-3-35-40","url":null,"abstract":"Malfunctions in the functioning of the blood coagulation system are often found in elderly patients. Age and the presence of concomitant diseases are not only risk factors for thrombosis, but also increase the likelihood of bleeding. This significantly complicates the problem of choosing anticoagulant therapy. Thus, chronic heart failure, chronic obstructive pulmonary disease, diabetes mellitus, cancer, etc. are established prothrombotic risk factors. Acquired hemophilia and von Willebrand syndrome, factor XI or vitamin K deficiency, thrombocytopenia and thrombocytopathy, on the contrary, may be risk factors for bleeding. Additional difficulties in prescribing anticoagulant therapy to elderly patients arise due to common problems in old age: renal failure, impaired liver function, polypharmacy, etc. However, the presence of these features is not a reason to refuse anticoagulant therapy, since the risk of thrombosis in such patients, as a rule, exceeds the risk of bleeding. This review details the problems that a clinician may face when prescribing anticoagulant therapy to elderly patients and provides recommendations for overcoming them. It is also reported that in the absence of contraindications, direct oral anticoagulants are the best option for the treatment of venous thromboembolic complications.","PeriodicalId":472385,"journal":{"name":"A I Burnasyan Federal Medical Biophysical Center Clinical Bulletin","volume":"205 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135663105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Application of Drugs Based on Hyaluronic Acid and Polylactic Acid in Male Genital Surgery 基于透明质酸和聚乳酸的药物在男性生殖器手术中的应用

A I Burnasyan Federal Medical Biophysical Center Clinical Bulletin Pub Date : 2023-10-01 DOI: 10.33266/2782-6430-2023-3-27-29

R.T. Aliev, I.P. Silkin, R.R. Aliev, A.G. Martov

引用次数: 0

Modern Problems of Medical Ethics and Deontology 医学伦理学与义务论的现代问题

A I Burnasyan Federal Medical Biophysical Center Clinical Bulletin Pub Date : 2023-10-01 DOI: 10.33266/2782-6430-2023-3-14-17

O.S. Orlova, N.V. Aleksina

引用次数: 0